I simply updated the price & royalties in the Karst Peak
valuation (and used a 50% drug price discount for RoW),
and the model suggests $32 valuation today. Only $200m placeholder for NNZ.
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-4548
-
- There are more pages in this discussion • 6,324 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$21.22 |
Change
0.770(3.77%) |
Mkt cap ! $2.716B |
Open | High | Low | Value | Volume |
$20.56 | $21.55 | $20.54 | $4.487M | 212.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 59 | $21.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.23 | 28 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 144 | 21.210 |
2 | 85 | 21.200 |
4 | 197 | 21.190 |
5 | 433 | 21.180 |
3 | 660 | 21.170 |
Price($) | Vol. | No. |
---|---|---|
21.230 | 41 | 3 |
21.240 | 25 | 1 |
21.250 | 262 | 3 |
21.260 | 155 | 2 |
21.270 | 712 | 4 |
Last trade - 12.29pm 16/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, CEO / Non-Exec Director
James Graham / Dr Alan Dunton
CEO / Non-Exec Director
SPONSORED BY The Market Online